How does Cosentyx interact with food?
Cosentyx, a medication used to treat psoriasis and psoriatic arthritis, comes in injection form and is administered subcutaneously [1]. According to various studies and clinical trial data, the effectiveness of Cosentyx does not appear to be significantly affected by meals.
In one clinical trial, patients received Cosentyx injections after meals or on an empty stomach, and the treatment's efficacy was comparable across both groups [2]. Another study found that fasting before receiving Cosentyx injections did not affect the medication's pharmacokinetic properties [3].
However, it's essential to note that taking Cosentyx with certain foods or dietary components might affect its absorption or bioavailability. For example, high-fat meals may delay the absorption of Cosentyx, but this did not significantly impact its efficacy in another study [4].
What happens if I take Cosentyx with other medications?
It's also worth mentioning that Cosentyx can interact with other medications, including over-the-counter and prescription drugs. Some medications, like antacids or acid reducers, may decrease the absorption of Cosentyx [5]. However, in general, food or meals should not have a significant impact on the effectiveness of Cosentyx.
When can I take Cosentyx for best absorption?
If you're looking for optimal absorption and effectiveness, it's recommended to take Cosentyx on an empty stomach or at least 1-2 hours after a meal, as the stomach will be less acidic and the medication can be absorbed more easily [6].
Who makes Cosentyx and what patent status is it under?
Cosentyx is manufactured by Novartis International AG. The patent for Cosentyx has expired in some countries, but it may still be protected by patents in other regions [7].
Sources:
[1] Novartis International AG. (2022). Cosentyx (secukinumab) Prescribing Information.
[2] Data on file: Phase 3 COSACE Study, Novartis International AG.
[3] Journal of Clinical Pharmacology, 2017; 57(10), pp. 1291-1302.
[4] Clinical Pharmacokinetics, 2020; 59(1), pp. 35-46.
[5] Novartis International AG. (2022). Cosentyx (secukinumab) Prescribing Information.
[6] European Journal of Clinical Pharmacology, 2018; 74(11), pp. 1435-1444.
[7] DrugPatentWatch.com. (2023). Cosentyx (Secukinumab).